腎足蛋白(NPHN)多克隆抗體
Polyclonal Antibody to Nephrin (NPHN)
NPHS1; CNF; Nephrosis 1; Congenital Finnish Type; Renal glomerulus-specific cell adhesion receptor
- 編號(hào)PAA937Hu02
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源多抗制備
- 宿主兔
- 效價(jià)-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原 RPA937Hu02-腎足蛋白(NPHN)重組蛋白
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 濃度0.5mg/ml
- 且適物種Mus musculus (Mouse，小鼠), Rattus norvegicus (Rat，大鼠)
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細(xì)胞術(shù)，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 565 ¥ 1319 ¥ 1884 ¥ 4710 ¥ 18840
- 欲了解實(shí)際交易價(jià)格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Used in DAB staining on fromalin fixed paraffin-embedded Kidney tissue
-
Figure. Western Blot; Sample: Recombinant NPHN, Human.
-
Western Blot; Sample: Rat Kidney lysate;
Primary Ab: 1μg/ml Rabbit Anti-Human NPHN Antibody
Second Ab: 0.2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
Western Blot; Sample: Mouse Kidney lysate;
Primary Ab: 1μg/ml Rabbit Anti-Human NPHN Antibody
Second Ab: 0.2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19)
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對NPHN的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別NPHN。
用法
Western blotting: 0.01-2μg/mL
Immunohistochemistry: 5-20μg/mL
Immunocytochemistry: 5-20μg/mL
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽性對照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA937Hu01 | 腎足蛋白(NPHN)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA937Hu03 | 腎足蛋白(NPHN)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA937Hu04 | 腎足蛋白(NPHN)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA937Hu02 | 腎足蛋白(NPHN)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA937Hu01 | 腎足蛋白(NPHN)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA937Hu03 | 腎足蛋白(NPHN)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA937Hu02 | 腎足蛋白(NPHN)多克隆抗體 | WB; IHC; ICC; IP. |
| MAA937Hu22 | 腎足蛋白(NPHN)單克隆抗體 | WB; ICC/IF |
| MAA937Hu21 | 腎足蛋白(NPHN)單克隆抗體 | WB |
| MAA937Hu23 | 腎足蛋白(NPHN)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA937Hu24 | 腎足蛋白(NPHN)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA937Hu25 | 腎足蛋白(NPHN)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA937Hu27 | 腎足蛋白(NPHN)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA937Hu29 | 腎足蛋白(NPHN)單克隆抗體 | WB; IHC; ICC; IP. |
| SEA937Hu | 腎足蛋白(NPHN)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| AEA937Hu | 抗腎足蛋白抗體(Anti-NPHN)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
| LMA937Hu | 腎足蛋白(NPHN)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Yonsei medical journal | The Level of Serum and Urinary Nephrin in Normal Pregnancy and Pregnancy with Subsequent Preeclampsia. [pubmed:28120572] |
| Experimental and molecular pathology | Alteration of Connexin43 expression in a rat model of obesity-related glomerulopathy. [pubmed:29246788] |
| British Journal of Haematology? | Renal protection by atorvastatin in a murine model of sickle cell nephropathy [Pubmed:29527679] |
| Journal of Clinical Medicine | Multiplex Bead Array Assay of a Panel of Circulating Cytokines and Growth Factors in Patients with Albuminuric and Non-AlbuminuricDiabetic Kidney Disease [Pubmed: 32961903] |
| Disease Markers | Urinary Matrix Metalloproteinase-9 and Nephrin in Idiopathic Membranous Nephropathy: A Cross-Sectional Study [34707724] |
| Biomed Rep | Early biomarkers of nephrotoxicity associated with the use of anti-VEGF drugs [Pubmed:35620307] |
